The fine line between abuse and fair use at the PTAB
Hedge fund manager Kyle Bass has outraged the pharma and biotech industries by seeking to invalidate their patents at the PTAB, with some observers linking his attacks to short-selling of company stocks. Michael Loney reports on a controversy that goes to the heart of the US patent system
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
